This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
mdm2
MDM2
E3 ubiquitin ligase and primary p53 negative regulator; MDM2 ubiquitinates p53 for proteasomal degradation. Amplified in ~7% of cancers, especially well-differentiated liposarcoma. MDM2 inhibitors (AMG-232, milademetan) restore p53 activity in TP53 wild-type tumors.
Entry Metadata
| Field | Value |
|---|---|
| ID | mdm2 |
| Name | MDM2 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Lane DP, Hall PA. MDM2 — arbiter of p53's destruction. Trends Biochem Sci. 1997;22(10):372-374. · PubMed 9357318
- Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-848. · PubMed 14704432
- Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2012;30(32):3980-3987. · PubMed 23032616